deltatrials
Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01723488

A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 (T808)

A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808

Sponsor: Avid Radiopharmaceuticals

Interventions [F18] T808
Updated 6 times since 2017 Last updated: Jul 18, 2013 Started: Jul 31, 2012 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.

This EARLY_PHASE1 trial investigates Alzheimers Disease and is currently terminated or withdrawn. Avid Radiopharmaceuticals leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated EARLY_PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated EARLY_PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated EARLY_PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated EARLY_PHASE1

    Phase: Phase 0EARLY_PHASE1

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    Terminated Phase 0

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Avid Radiopharmaceuticals
Data source: Avid Radiopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .